GSK: Jemperli Achieves Sustained Clinical Complete Responses in DMMR/MSI-H Locally Advanced Rectal Cancer
July 14, 2026
July 14, 2026
LONDON, England, July 14 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 13, 2026:
* * *
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
* Primary objective met in interim analysis, with clinically significant rate of participants showing no detectable signs of cancer one year or more after treatment
* Results support pot . . .
* * *
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
* Primary objective met in interim analysis, with clinically significant rate of participants showing no detectable signs of cancer one year or more after treatment
* Results support pot . . .